Vulvar cancer
ICD-10 C51 · ICD-11 2C70

Treatment of Metastatic or Recurrent Unresectable Squamous Cell Carcinoma of the Vulva

Clinical Scenario

This protocol applies to patients with squamous cell carcinoma of the vulva that has become metastatic or has recurred in a form that is no longer amenable to surgical resection. In this setting, systemic therapy is the primary approach.

Disease Setting

Metastatic or recurrent unresectable squamous cell carcinoma of the vulva represents a clinically challenging situation with limited standard options. Platinum-based combination chemotherapy is the established consideration for first-line systemic treatment in this population.

Treatment Approach

Immune checkpoint inhibitors represent one category of agents relevant in this setting. Additional systemic options exist, though no single drug carries specific approval for this indication. The full structured protocol details the complete evidence-based approach.

Instant Access to Structured Evidence-Based Regimens

References

  1. Platinum-based combination chemotherapy should be considered as first-line treatment for metastatic or recurrent unresectable disease [III, B].
  2. After progressing to platinum-based first-line chemotherapy, there are no standard treatments. Immune checkpoint inhibitors can be considered as monotherapy [III, B].
  3. Chemotherapy or epidermal growth factor receptor targeting inhibitors may be considered as possible alternatives, taking into account that there is no specific approval for any drug [III, C].
DOI: 10.1136/ijgc-2023-004486 View source ↗